TIAA FSB’s TG Therapeutics TGTX Stock Holding History

TIAA FSB’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-45,200	Closed	-$642K	–	370
2018 Q1	$642K	Hold	45,200	–	–	﹤0.01%	315
2017 Q4	$371K	Buy	+45,200	New	+$395K	﹤0.01%	366

Other funds holding TGTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TIAA FSB's TGTX Position: Q2 2018 in Review

TIAA FSB sold out of TG Therapeutics (TGTX) in Q2 2018, closing a stake of 45,200 shares — an estimated $642K sold.

TIAA FSB first reported a position in TGTX in Q4 2017 and held it in 2 quarters. The position peaked at $642K in Q1 2018. 132 funds tracked by Wall St. Rank hold TGTX as of Q2 2018.

TIAA FSB reported no remaining TG Therapeutics position as of Q2 2018 after selling out during the quarter.
TIAA FSB sold 45,200 TG Therapeutics shares in Q2 2018, an estimated $642K.
TIAA FSB first reported a position in TG Therapeutics in Q4 2017 and held it in 2 quarters.
TIAA FSB's TG Therapeutics position peaked at $642K in Q1 2018.
132 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2018.

Based on TIAA FSB's 13F filing for Q2 2018, filed 20 Jul 2018.